Call
+918447748545

Published on: Jul 17, 2020
2 minute read
By: Dr Rajan Choudhary

MRNA Vaccine Against SARS CoV2

An mRNA Vaccine against SARS CoV2

We have previously discussed vaccines against SARS-CoV-2, the virus responsible for COVID-19. On the 14th of July, a preliminary study was published in the New England Journal of Medicine, an internationally reputable medical journal. This study looks at mRNA vaccines in Phase 1 human clinical trials, a first for the virus. Here we will discuss what this means and the results of the study.

mRNA vaccine

Vaccines target the immune system’s memory by presenting them with pieces of these infective diseases. The small amounts do not cause any infective symptoms, but if the person is infected later in life their body will mount a quicker response and prevent them from falling ill. These vaccines can contain broken up parts of the organisms, “dead” organisms or “live” versions that have been severely weakened so they cannot cause any harm.

In 2018 a new type of vaccine was described. Instead of using pre-made protein markers that identify infectious organisms, mRNA vaccines contain genetic material with instructions to produce these markers. Once injected, the person’s cells use these instructions to produce copies of these protein markers. These markers are displayed on the surface of the cell, which in turn is recognized by the immune system, initiating an immune response and producing protective antibodies.

BENEFITS

A major advantage of RNA vaccines is the ease by which they can be made in a laboratory from a DNA template. During a pandemic, this would result in a rapid response and vaccine against a new disease. Conventional vaccines require the use of chicken eggs or cells to produce the vaccines, which can be expensive and time-consuming. These vaccines can be delivered via injections into the skin, blood, muscle, or organs, needle-free into the skin, or via nasal spray. Because these vaccines are so new, we still do not know the best way to deliver it.

Because these vaccines are not made with parts of infective organisms or from live organisms, they are not infectious and will not cause harm through a strong immune response to the vaccine itself, or by causing the disease they aim to vaccinate against. They also appear to be very efficient at generating a reliable immune response to produce antibodies and are well tolerated with few side effects.

NEEDS IMPROVEMENT

Because these types of vaccines are so new there is still a lot we do not understand about them. They may cause unintended effects that we have not yet encountered in human clinical studies. These vaccines also need to be frozen or refrigerated, and so would not be suitable for countries with limited or no refrigeration facilities.

COVID

The SARS-CoV-2 mRNA vaccine codes for one of the virus’ surface spike proteins, responsible for recognizing target cells and fusing the virus into the cell for entry and infection. It was previously recognized as a target for the SARS and MERS viruses.

45 participants received 2 intramuscular injections 28 days apart. None of the participants had any serious side effects after the first injection, or any side effects significant enough to stop the trial. Many had minor to moderate side effects after their second injection (such as fatigue, chills, headache, myalgia, and pain at the injection site), and half the participants taking high dose vaccines had febrile side effects. Overall the side effects were rated as acceptable.

Prior to the vaccine trials, none of the participants had any antibodies against COVID, or any capacity to stop a COIVD infection. After the injections, all participants had noticeable increases in antibodies produced, measurable in their blood. After 43 days, the participant's blood had enough antibodies to reduce infection by SARS-CoV-2 by over 80%.

What is the takeaway? The vaccine is capable of producing an adequate response to protect the vaccine recipient without eliciting any major side effects. These results will be used in phase 2 clinical trials (enrolment began in May) and a phase 3 trial in July 2020. Essentially this means further human trials to further look for side effects in a larger number of volunteers with a more diverse health profile.

This represents an interesting development in producing a rapid vaccine against a new virus responsible for a world-changing pandemic. This new type of vaccine may be the future of vaccines for a broader range of viruses, bacteria, and even cancers.

Read Blog

Tuberculosis Symptoms and Treatment: Early Signs, Diagnosis, and Recovery

Tuberculosis (TB) is one of the oldest known infectious diseases and continues to be a major public health concern, especially in developing countries. India accounts for a significant proportion of global TB cases, despite advances in diagnosis and treatment. The good news is that tuberculosis is preventable, treatable and curable when detected early and managed properly.

Understanding tuberculosis symptoms and treatment is critical for reducing disease spread, preventing complications and achieving complete recovery.

What Is Tuberculosis?

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can also involve other parts of the body such as:

lymph nodes
bones and joints
kidneys
brain

TB spreads through the air when an infected person coughs, sneezes or speaks.

Why Tuberculosis Remains a Major Health Issue

According to the World Health Organization and ICMR data:

millions of new TB cases are reported annually
delayed diagnosis increases transmission
incomplete treatment leads to drug resistance

Early detection and treatment are key to TB control.

Common Tuberculosis Symptoms

TB symptoms often develop gradually and may be mild in the early stages, leading to delayed diagnosis.

Persistent Cough

A cough lasting more than two to three weeks is a hallmark symptom of pulmonary TB.

The cough may:

be dry or productive
worsen over time
sometimes produce blood

Fever and Night Sweats

Low-grade fever, especially in the evenings, is common.

Night sweats that soak clothing or bedding are a classic TB sign.

Unexplained Weight Loss

TB increases metabolic demand and reduces appetite, leading to significant weight loss.

Fatigue and Weakness

Persistent tiredness and reduced stamina occur due to chronic infection.

Chest Pain

Chest discomfort or pain may occur during coughing or breathing.

Symptoms of Extra-Pulmonary TB

When TB affects organs outside the lungs, symptoms depend on the site involved and may include:

swollen lymph nodes
bone or joint pain
headaches or neurological symptoms
urinary issues

Why TB Symptoms Are Often Ignored

Many TB symptoms resemble common infections or general weakness.

This leads to:

delayed medical consultation
prolonged transmission
disease progression

Awareness improves early detection.

How Tuberculosis Is Diagnosed

Diagnosis involves a combination of:

sputum tests
chest X-ray
molecular tests such as CBNAAT
blood tests and imaging for extra-pulmonary TB

Early and accurate diagnosis is essential for effective treatment.

Tuberculosis Treatment Explained

TB treatment involves a combination of antibiotics taken over a fixed duration.

Standard TB Treatment

For drug-sensitive TB, treatment typically lasts:

6 months

The regimen includes multiple antibiotics taken in phases to ensure complete bacterial clearance.

Importance of Treatment Adherence

TB bacteria are slow-growing and resilient.

Stopping treatment early can result in:

incomplete cure
relapse
drug-resistant TB

Completing the full course is essential.

Drug-Resistant TB

If TB bacteria become resistant to standard drugs, treatment becomes longer and more complex.

Drug-resistant TB requires:

specialised medications
longer treatment duration
close medical supervision

Prevention of resistance depends on correct treatment from the start.

Side Effects of TB Treatment

Some individuals may experience side effects such as:

nausea
loss of appetite
mild liver enzyme changes

Most side effects are manageable with medical guidance and do not require stopping treatment.

TB and Public Health

TB is not just an individual health issue but a community concern.

Effective TB control requires:

early diagnosis
treatment adherence
contact tracing
public awareness

India’s national TB elimination programmes focus on these strategies.

Preventing Tuberculosis

Preventive measures include:

early detection and treatment of active TB
improving nutrition and immunity
adequate ventilation in living spaces
screening close contacts

BCG vaccination offers partial protection, especially in children.

Living With and Recovering From TB

With proper treatment:

symptoms gradually improve
infection becomes non-contagious
normal life can be resumed

Regular follow-up ensures complete recovery.

When to Seek Medical Help

Consult a healthcare provider if experiencing:

cough lasting more than two weeks
unexplained weight loss
persistent fever or night sweats
blood in sputum

Early action saves lives and prevents spread.

Long-Term Outlook After TB Treatment

Most individuals who complete treatment:

recover fully
regain normal lung function
return to daily activities

Long-term complications are rare with timely care.

Conclusion

Tuberculosis symptoms and treatment must be understood clearly to combat this preventable and curable disease. Persistent cough, fever, night sweats and weight loss should never be ignored. Early diagnosis, complete treatment adherence and regular follow-up are essential for curing TB and preventing transmission. With proper medical care and public awareness, tuberculosis can be effectively controlled and eliminated as a public health threat.

References

Indian Council of Medical Research (ICMR) – Tuberculosis Epidemiology and Treatment Guidelines
World Health Organization (WHO) – Global Tuberculosis Report
National Tuberculosis Elimination Programme (NTEP) – Government of India
Lancet Infectious Diseases – TB Diagnosis and Treatment Outcomes
National Family Health Survey (NFHS-5) – Infectious Disease Indicators
Statista – Global Tuberculosis Burden and Trends

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.